OPR - Delayed Quote • USD TNGX Aug 2024 20.000 put (TNGX240816P00020000) Follow 10.30 0.00 (0.00%) At close: February 21 at 10:37 AM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for TNGX240816P00020000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: TNGX Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights Tango Therapeutics to Participate in Upcoming Investor Conferences Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25% Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates
